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Abstract: Porous composite scaffold using an alginate and bioactive glass ICIE16M was synthesized 
by a simple freeze-drying technique. The scaffold was characterized using compression testing, 
Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray 
diffraction (XRD), X-ray microtomography (XMT) and scanning electron microscopy (SEM). The 
bioactivity of the scaffold was evaluated by its ability to form apatite on its surface in simulated 
body fluid (SBF). The data collected showed evidence that the novel material produced had an 
appropriate pore size for osteoconduction, with an average pore size of 110 µm and maximum pore 
size of 309 µm. Statistical analysis confirmed that the glass filler significantly (P < 0.05) increased the 
collapse yield of the scaffolds compared with pure alginate scaffolds. The ICIE16M glass had an 
amorphous structure, favorable for bioactivity. 
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1. Introduction 
Fractures impose a huge burden on healthcare systems. Autografts, allografts and metals have 
numerous limitations, including tissue availability/compatibility, pain, bleeding and potential for 
infection. There is a great need to develop synthetic bone graft substitutes to meet the 
epidemiologically driven demand. The ideal bone substitute should be biocompatible, porous, 
bioactive, bactericidal and mechanically stable. Interconnected porosity within the system is required 
to facilitate cell growth and vascularization. 
Bone scaffolds are materials placed in an area of bone loss with the function of aiding hard tissue 
repair or supplementing bone tissue volume to facilitate the placement of an implant. The use of 
synthetic bone scaffolds is increasing due to the potential of these materials to alter the healing 
process. Additionally, they can be used for drug and growth factor delivery [1–3]. Although 
autografts and allografts remain the gold standard for bone scaffolds [4], various complications and 
morbidity [5–8] can be avoided with the use of synthetic bone scaffolds. 
The use of bone substitutes is common in reconstructive surgery, including plastic surgery, 
orthopedics and, increasingly, in dentistry [9–11]. The economic impact of bone defects is huge, with 
an approximate annual cost of 2.5 billion dollars in the United States alone [12,13]. Furthermore, there 
J. Funct. Biomater. 2019, 10, 15 2 of 14 
are in excess of 2.2 million bone grafting procedures performed each year worldwide [14]. These 
figures can be expected to increase given the aging population, with an ever-increasing demand from 
patients for predictable outcomes following surgical interventions.  
Bone scaffolds provide a surface for bone cells to colonize and proliferate by providing 
mechanical stability and protection to the area and cell attachment sites [15]. Current literature [16–19] 
indicates that an average pore size of 100 µm in a bone scaffold is required in an interconnected 
arrangement for osteoprogenitor cell colonisation to allow new bone tissue to be formed. For larger 
defects, mature bone formation requires angiogenesis and invasion of nerve fibers. Much larger pores 
of 300 µm and upward are shown to be necessary for these processes [13,20,21]. However, an 
increased pore size may reduce cell adhesion due to a reduced volume to surface area ratio [15]. 
Porosity (ideally 90% of the volume of the scaffold) provides not only an increased surface area for 
cell migration, attachment and proliferation, but also for the diffusion of nutrients to the bone forming 
cells and for the passage of their waste products away from the local area [17]. Along with being 
adequately porous, an ideal bone scaffold should be biocompatible, bioactive, biodegradable, 
mechanically stable and reproducible for mass production.  
A variety of fabrication techniques are used in the bone tissue engineering field [22–26], such as 
particle leaching, sol-gel foaming, electrospinning [27–29], phase-separation, [30,31] freeze-drying, 
[32,33] and 3D printing [2]. Each technique has its advantages and disadvantages. For example, in 
the sol-gel foaming method, glass may degrade too rapidly before the bone can regenerate. The 
freeze-drying technique, however, is simple, does not require any expensive equipment and offers 
the benefit of being facilitating tailoring of the pore structure through variation of the lyophilisation 
process [21]. 
Alginate is polysaccharides obtained from certain species of brown algae and seaweed. It has 
long been used for many biomedical applications due to its biocompatibility, low toxicity and 
relatively low cost. It has been used as three-dimensional cell matrices to good effect, but it is now 
finding new applications in bone scaffold research [34–36]. Alginate can be easily shaped and 
manipulated. In addition, it is also a safe material and, hence, is commonly found in wound dressings 
such as Kalginate TM and as a filler material in the food industry. Alginate is a linear polymeric acid 
composed of 1, 4-linked β-d-mannuronic acid (M) and α-l-guluronic acid (G) residues. It forms 
hydrogel when certain divalent cations, such as Ca2+ or Sr2+, are chemically crosslinked through ionic 
interaction between the cation and the carboxyl functional group of G units located on the polymer 
chain [18,20,21,37]. Alginates are shown to be able to support the nucleation of hydroxyapatite 
crystals on their surface when submerged in body fluids and SBF [38]. Previous work [20,21,35,36] 
showed the plausibility of using alginate to produce sufficiently porous bone scaffold materials.  
For several decades, the bioactive potential of ceramic-based materials in relation to bone 
formation was investigated, stemming from the work of Larry Hench [39], who developed the first 
such material, Bioglass® 45S5. This work led to a snow-balling of interest in this field, giving rise to 
materials now routinely used to support bone healing, coat orthopedic implants and improve the 
interface between prostheses and living tissues [40]. A bioactive glass has been in use clinically as a 
synthetic bone void filler under the product name ‘Perioglas’ and ‘Novabone’ since 1993. 
Furthermore, such materials have the desired physical properties for use in various bone scaffold 
applications [41–43].  
Bioactive silicate glasses are recognized as class ‘A’ bioactive materials because they offer high 
bioactivity involving both osteoconduction and osteoinduction. They are capable of reacting with the 
physiological fluids forming tenacious bonds to bone through the formation of bone-like 
hydroxyapatite layers leading to effective biological interaction and fixation of bone tissue with the 
material surface [5,6]. The bioactivity of glasses depends on their network connectivity (NC), which 
should be close to two [44].  
Sriranganathan et al. [45] and Huang et al. [46] reported that Bioglass® 45S5 has a slow 
degradation rate and HA formation rate when compared to other bioactive glasses, which makes it 
hard to predict the rate of new tissue formation in vivo. Moreover, it is difficult to induce porosity in 
scaffolds made from the Bioglass®. The main reason for this is that there is a small difference between 
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its glass transition temperature and its crystallization temperature; the so-called processing or 
sintering window. These difficulties can lead to the formation of a scaffold that has a low 
strength/cohesivity [47]. For bioactive glasses to be effective as bone graft substitutes, they must be 
sintered into porous scaffolds without crystallization [46]. 
The first amorphous melt-derived bioactive glass scaffold suitable for bone applications was 
synthesized using the polymer foam replication technique with glass composition 13-93 [48]. This 
glass composition has a higher SiO2 content and low phosphorus content. Low phosphorus is 
associated with less bioactivity. Donnell et al. [49] reported that increasing the phosphorus content is 
associated with increased bioactivity. Secondly, it degrades at a rate that is even slower than Bioglass® 
45S5 [46]. However, an advantage that 13-93 has over Bioglass® 45S5 is that it has a much larger 
sintering window, which means that porous 3D scaffolds can be created and sintered without 
crystallization. However, although the scaffolds made using the polymer foam replication technique 
[48,50] have significant porosity, they are very brittle [47]. 
The development of composite materials is common practice in tissue engineering and materials 
science. Composite materials can offer the beneficial properties of multiple materials. Indeed, bone 
tissue itself is a composite material of organic and inorganic phase [51]. 
In the light of the above, the objective of the study was to synthesize a novel, biocompatible 
composite material with sufficient porosity and with features suited to bone scaffold applications 
using a simple, reproducible freeze-drying technique. The composite is made by combining an 
alginate with strontium (Sr) and zinc (Zn) containing bioactive glass ICIE16M. The ICIE16M is 
modified from ICIE16 [52,53]. The glass ICIE16 has bioactivity comparable to 45S5, but large sintering 
window. In their study, Echezarreta-López et al. [52] showed the release of Sr and Zn ions from the 
ICIE16M glass. The presence of strontium and zinc in ICIE16M has a beneficial effect on bone growth 
[54,55]. Strontium and zinc both act by increasing bone formation and decreasing bone resorption, thus 
rebalancing bone turnover in favor of bone formation, an effect that results in increased bone mass and 
strength [56,57]. The inclusion of the glass filler is used to increase the strength of a pure alginate scaffold 
and promote bioactivity, which will promote in situ osseointegration [58,59]. 
2. Materials and Methods 
2.1. Materials 
Sodium alginate was obtained from Fisher Scientific Ltd (Leicestershire, UK), while calcium 
chloride and sodium lauryl sulphate were obtained from Sigma-Aldrich Ltd (Gillingham, UK). 
ICIE16M glass powder, which is a modification of ICIE16 (see Table 1), was synthesized as in 
previous protocols [52–54]. Compositions for ICIE16 and ICIE16M are given in Table 1. All the oxides 
were mixed together in the proportions as mentioned in Table 1 and heated to 1420 °C in a platinum 
crucible for 1.5 h, followed by quenching in water at room temperature [52–54]. The coarse frit form 
of the glass was collected and dried overnight. The glass frits were milled to powder form using a 
gyro-mill (Gyro mill, Glen Creston, London, UK) and sieved at <38 µm (Endecotts Ltd., London, UK). 
The glass particles were characterized by differential scanning calorimetry (DSC) and X-ray 
diffraction (XRD) techniques. 
Table 1. Compositions (mol. %) of alginate and bioactive glass (ICIE16M) and ICIE16 [52–54]. 
 SiO2 Na2O CaO SrO K2O MgO ZnO P2O5 
ICIE16M 49.46 6.60 27.27 3.00 6.60 3.00 3.00 1.07 
ICIE16 49.46 6.60 36.27 0 6.60 0 0 1.07 
2.2. Methods 
2.2.1. Glass Characterization 
The DSC for ICIE16M glass particles was conducted to determine the glass transition 
temperature (Tg) and crystallization temperature (Tc) [60–64]. A 50 µg sample of the glass powder 
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was heated at rates of 10 °C min−1 and 20 °C min−1 using Stanton-Redcroft DSC 1500 (PL Thermal 
Sciences, Epsom, UK) series. A starting temperature of 50 °C was used and final temperature of 1100 
°C using a Nitrogen atmosphere.  
X-ray diffraction spectrometry was performed on the samples (in powder form in silicone 
sample holder) using the PANalytical X'Pert Pro diffractometer ( Malvern, UK) powered by Philips 
PW 1729 X-ray generator. Phase identification was carried out by means of the software program 
PANalytical High Score Plus (Version 2.2b, Malvern Panalytical Ltd, Malvern, UK). Diffraction data 
is acquired by exposing powder samples to Cu-Kα X-ray radiation, which has a characteristic 
wavelength () of 1.5418 Å.  X-rays were generated from a Cu anode supplied with 40 kV and a 
current of 40 mA. 
2.2.2. Fabrication of Composite Scaffold 
One-hundred mL of deionized water was heated and maintained at a constant temperature of 
50 °C in a 300 mL pyrex beaker. Three grams of alginate powder were added slowly along with 3 
grams of ICIE16M glass powder and 100 mL of 0.2% sodium lauryl sulphate solution. The mixture 
was stirred at a constant rate of 2000 rpm for 20 min. The solution was poured immediately into 15 
equal-sized cylindrical specimen tubes quenched in liquid nitrogen. After 5 min, the tubes were 
transferred into a commercial freezer at −20 °C. In the case of 15 control specimens, glass powder was 
not added in order to compare the mechanical properties of pure alginate scaffold with the composite 
scaffolds. 
The samples were freeze-dried for 20 h at a pressure setting of 6 mbar and a temperature of −50 
°C. These samples were then soaked in a 1% calcium chloride crosslinking solution for 3 h and 
thereafter refrozen in a commercial freezer at −20 °C for 48 h. The samples were then feeze-dried for 
a second cycle under the same conditions as before, resulting in a final composite bone scaffold being 
yielded.  
The density of the samples were calculated using the standard formulas:  
Cross sectional area A = πr2 µm2 (1) 
where r is the radius of the cylindrical sample 
Volume of the sample (µm3) = Ah (2) 
where h = the height (density = mass/volume g/µm3). 
2.2.3. Characterization of Scaffolds 
Fourier-transform infrared spectroscopy (FTIR) technique was used as a quality control check to 
ensure that chemical crosslinking occurred within the body of the scaffold during fabrication using 
FTIR Spectrum GX with Spectrum v5.3.1 software (NICOLET IS10 FT-IR SPEC, Thermofisher, 
Waltham, MA, USA). FTIR provided detailed information on the chemical groups contained within 
the samples. Changes to the sample chemical structure can, in some instances, be shown by a shift in 
the original trace to different wave numbers. Solid samples of crosslinked and non-crosslinked 
scaffolds were tested between 4000 and 400 cm−1. 
The specimens (1 mm × 2 mm × 3 mm) from composite scaffolds were prepared for X-ray 
microtomography (XMT). They were scanned using the in-house MuCAT 2 XMT scanner [65] with a 
15 µm resolution. Image J (v1.43) and Drishti v2.4 software packages (developed by Ajay Limaye, 
Australian National University Supercomputer Facility, Australia) were used to assess XMT data. 
Average pore size calculations were completed using the ‘Thickness’ algorithm in the ‘Bone J’ plugin 
for Image J.  
Scanning electron microscopy (SEM) of composite scaffolds was conducted. Secondary electron 
beam images were taken up to 100×–800× magnification with SEM (JSM-840A, JEOL, Tokyo, Japan) 
to gain detailed information on scaffold architecture and the presence of any crystals following 
submersion of the scaffolds in SBF.  
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Scaffolds were subjected to compression testing using an Instron 5567 universal testing machine 
(Instron Corp., Norwood, MA, USA). The samples were cut into cylinders of 8 mm diameter and 8 
mm length with plane-parallel ends. The length and diameter were measured using a digital 
micrometer. Each sample was compressed with an overhead speed of 2 mm min−1 using a 1 kN load 
cell. The stiffness (Young’s Modulus E) of the scaffolds was obtained by fitting a tangent line to the 
initial part of the stress-strain plot. The gradient of this line is considered as the modulus of elasticity. 
A horizontal line was fitted against the plateau of the load versus time curve of the sample and the 
corresponding value of compressive load was taken for each specimen. The fracture stress was 
measured from the ‘load at collapse’ and cross-sectional area. 
2.2.4. Statistical Analysis 
All pore sizes are expressed as mean ± standard deviation. Differences in collapse stress and 
Young’s modulus of glass reinforced and pure alginate scaffolds were assessed using the Student’s 
t-test, where a P value of less than 0.05 was considered significant. 
2.2.5. Evaluation of Bioactivity of Scaffolds in Simulated Body Fluid  
Reagents for preparation of simulated body fluid (SBF) solution [66]: Sodium chloride (NaCl), 
sodium hydrogen carbonate (NaHCO3), potassium chloride (KCl), di-potassium hydrogen phosphate 
trihydrate (K2HPO4.3H2O), magnesium chloride hexahydrate (MgCl2.6H2O), calcium chloride 
(CaCl2), sodium sulfate (Na2SO4), tris-hydroxymethyl aminomethane (TRIS) (HOCH2)3CNH2), 1M 
HCl solution.  
A solution of SBF was prepared according to the published method [66]. Composite scaffold 
samples were crushed in a ball shaker for exactly 1 min. The samples were weighed and the amount 
of SBF required for each sample was calculated according to the equation: 
Volume of SBF needed = sample weight (g) × 50 mL/0.075 g [66]  
The specimens were placed in an agitator at 37 °C and the pH value was adjusted to 7.4 [67]. The 
solution was filtered at 8 h, 24 h, 120 h and 336 h (two weeks). The filtered scaffold material was 
washed with ethanol. SEM was performed on these samples to assess the formation of any crystals. 
3. Results and Discussion 
3.1. DSC Analysis of ICIE16M Glass Powder 
The trace from the DSC technique is shown in Figure 1. It presents the thermal changes occurring 
during the heating of a glass powder sample at a constant rate. Point A represents the first glass 
transition phase of the glass powder at 596 °C and point B represents the second glass transition 
temperature at 672 °C. ‘C’ represents the crystallization temperature range of the glass lying between 
825 °C and 945 °C. It is worth mentioning here that the DSC test was conducted on five samples of glass 
ICIE16M. Figure 1 presents a representative curve. The deviation in the results was less than ± 0.2%. 
The sintering window was greater than 200 °C. The sintering window is defined as Tc − Tg, 
where Tc is the glass crystallization temperature and Tg is the glass transition temperature. The glass 
is most stable in a non-crystalline atomic arrangement. Amorphous atomic arrangements are believed 
to lead to the formation of an ‘open atomic network,’ which increases the in-situ reactivity of bioactive 
glasses. A stable and ordered crystalline atomic arrangement, by contrast, resists ionic dissolution in 
solution, so less reactive surface groups are made available for the nucleation of new crystals on their 
surface [68]. 
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Figure 1. Differential scanning calorimetry (DSC) trace of ICIE16M glass powder at a heating rate of 10 °C min−1. 
3.2. X-Ray Diffraction Analysis of ICIE16M Bioactive Glass 
The curve obtained from XRD, as shown in Figure 2, confirms the lack of any significant crystal 
phases within the ICIE16M glass filler used in this work. Crystal phases are usually represented in the 
XRD trace by peaks and crystallization is known to reduce bioactivity [68,69]. In this study, XRD traces 
lacks any notable peaks. The ‘peaks’ observed in this graph are simply artefacts of the XRD process. 
 
Figure 2. XRD trace of ICIE16M glass powder. 
3.3. Fourier Transform Infrared Spectroscopy Analysis of Crosslinking 
FTIR was used to compare the chemical composition of both non-crosslinked and crosslinked 
samples of the scaffold produced. The overlay FTIR trace in Figure 3 is concurrent with a previous 
study [16], indicating that the submersion of scaffolds in a crosslinking solution of calcium chloride 
solution for 3 h produced a notable chemical change in the scaffold and confirms crosslinking of the 
alginate polymer chains [16]. Characteristic portions of the trace are the hydroxyl bend at 3600 to 3000 
cm−1 and the carbonyl (C=O) group represented by the peak (wave number labelled above) at 
approximately 1600 cm−1. There is an observed difference in wave number for the carbonyl group 
peak of approximately 9 cm−1, concurrent with the current literature [16]. 
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Figure 3. An overlay trace of FTIR data: Non-crosslinked and crosslinked scaffold samples in 
composite alginate and bioactive glass scaffold. 
3.4. X-Ray Microtomography and Scanning Electron Microscopy Imaging of Scaffolds 
X-ray microtomography (XMT) (Figure 4) and SEM (Figure 5) provide valuable information on 
the architecture of the pores contained within the scaffold material. The developed scaffolds were 
analyzed in 3D using the Drishti v2.4 software (developed by Ajay Limaye, Australian National 
University Supercomputer Facility, Australia) that allowed investigating qualitatively the 
distribution and interconnectivity of the pores within the sample. The 3D computer rendered images 
show that the composite scaffold exhibits an extensive, interconnected porous network throughout 
its structure Figure 4a,b. Computer analysis of the XMT stack data allowed for quantification of the 
pore sizes contained within the scaffold. Average pore sizes within the produced scaffolds were 
calculated to be 109.8 µm ± 39.8 µm (Table 2), therefore falling within the intended range. The high-
resolution images gained from SEM, as shown in Figure 5a,b, provide a greater understanding of the 
pores on the surface of the scaffolds produced. The image taken at higher magnification (Figure 5b) 
shows in details the morphology of the trabeculae within the composite scaffold. Current literature [70] 
indicates that osteoprogenitor cell colonization and proliferation is only made possible when average 
pore sizes of 100 µm are present to allow for cell movement (osteoblasts for example are approximately 
20–25 µm in size) and, importantly, the diffusion of nutrients to these cells and the movement of their 
waste products away from the area [17,70]. 
 
Figure 4. Computer rendered images taken using Drishti v2.4 of a composite scaffold showing (a) 
Porous structure of the scaffold in 3D and (b) zoomed section to better display the pore network (1 
mm across). 
a b 
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Figure 5. SEM Images of a composite scaffold. (a) Shows overall open pore architecture (100× 
magnification); (b) Shows the morphology of trabeculae (800× magnification). 
Interconnectivity of the pores allows for bone formation at the centre of the defect. Studies using 
nonporous scaffolds show promising bone formation at the peripheries of the defect only [70,71]. The 
maximum pore size obtained of 308.9 µm (Table 2) is also within the recommended range and reflects 
the natural architecture of trabecular bone. These larger pores are essential for mature bone formation 
in larger bone defects as they facilitate the permeation of blood vessels and nerve fibres. 
Table 2. Computer analysis of data obtained for composites scaffolds using XMT and SEM techniques. 
Mean trabecular thickness (µm) Max. Trabecular Thickness (µm) Average Density (g µm−3) 
41.715 ± 11.37 108.165 9.63 × 10−14 
Mean pore Size (µm) Max. pore Size (µm) SA to weight ratio (m2g−1) 
109.8 ± 39.81 308.865 0.005 
3.5. Compression Testing of Scaffolds 
Figure 6 shows the fabricated composite scaffold ready for compression testing. Compression 
tests were conducted for both pure alginate and composite samples. From the compression stress-
strain curve (Figure 7) of the scaffolds, the Young’s Modulus and collapse stress were obtained. As 
with all cellular solids, the developed scaffolds exhibit three characteristic phases of deformation 
under load. An initial linear trace labelled ‘A’ is seen where trabeculae within the body of the scaffold 
are deforming elastically up to the first peak (point of zero slope). Removal of the load in the range 
of this linear extension would result in the scaffold returning to its’ original form with no permanent 
damage. The plateau of the graph (Figure 7) labelled ‘B’ is the result of plastic deformation of the 
trabeculae when they are loaded beyond their collapse stress. Further loading of the specimen beyond 
this limit causes densification of the trabeculae [72], so an increase in the gradient of the curve is seen 
at Figure 7 labelled ‘C’. The tests have been conducted on 15 samples for each material (pure alginate 
and composite scaffolds). Figure 7 presents only three representative curves for each to visualize the 
repeatability of the results. From the plot, the point at which the curve tends to a plateau can be 
considered as the yield/collapse strength of the sample. The modulus of elasticity is calculated from the 
slope of the initial part of the stress-strain curve (Figure 7).  
a b 
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Figure 6. Composite scaffold after production for compression testing. 
 
Figure 7. Representative stress-strain curves for pure alginate and composite scaffolds. (a) Elastic 
deformation region; (b) Plastic deformation region; (c) Densification region. 
The data obtained from the compression testing (Table 3 and Figure 7) show that the inclusion 
of bioactive glass particle filler significantly increases (P = 0.02) the collapse stress/yield stress of the 
composite scaffolds (0.21 MPa) when compared with pure alginate scaffolds (0.16 MPa) produced in 
the same manner. The effect on modulus, however, was not significant (P ˃ 0.05). More studies are 
underway to further improve the mechanical properties by changing the composition of glass and by 
adding different proportions of alginate to bioglass.  
Table 3. Average Young’s Modulus and Collapse stress for pure alginate and composite scaffolds. 
Sample Type 
Average* Young’s 
Modulus (MPa) 
P value 
Average Collapse 
stress/yield stress (MPa) 
P value 
Alginate Scaffold 1.82 ± 0.99 
0.9 
0.159 ± 0.01 
0.022 
Composite Scaffold 1.83 ± 0.66 0.175 ± 0.04 
3.6. Bioactivity of Composite Scaffolds 
The composite scaffolds were assessed for bioactivity. An abundance of crystallites are seen to 
cover the surface of composite bone scaffold, as seen in the SEM image (Figure 8). Some specimens 
exhibited crystal growth after 120 h of submersion in SBF (Figure 6a–c), but for most samples, crystals 
appeared after two weeks, as shown in an earlier study [54,73]. The morphology of crystals also does 
not seem to be concurrent with that expected of hydroxyapatite crystals. These crystals exhibited 
cuboidal morphology (Figure 8 c,d) of calcite formations.  
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Figure 8. SEM of composite scaffold submerged in SBF for two weeks. (a) 5000×, (b) 10000×, (c) 15000×, 
(d) 60000×. 
ICIE16 is also known to form calcium phosphate crystals on its surface, which is a known 
precursor to hydroxyapatite after only 8 h submersion in SBF. After three days, typical needle-like 
hydroxyapatite crystals appear [53]. It could be that strontium substitution for calcium in ICIE16M 
bioactive glass has inhibited apatite-like phase formation. Moreover, bonding with alginate may have 
affected the bioactivity. The network connectivity of ICIE16M (calculated to be 2.13) may not be 
correct and Zn2+ and Mg2+ were probably acting more as network formers and NC may be close to 
2.53 [54,73]. Strontium and zinc present in ICIE16M are necessary for several enzymatic processes 
within the body. Strontium in the form of strontium ranelate is prescribed for its antiresorptive and 
anabolic properties to osteoporotic patients [74]. Previous studies [54,73] showed the release of 
strontium and zinc ions in SBF from ICIE16M using dissolution studies.  
4. Conclusions 
The ability to synthesize porous, biocompatible novel composite scaffold using alginate and 
bioactive glass (ICIE16M) containing strontium and zinc was demonstrated. Zinc and strontium are 
anabolic to bone and additionally zinc has antibacterial activity. The ICIE16M glass had an 
amorphous structure confirmed through XRD, and hence was favorable for bioactivity. The 
synthesized crosslinked and non-crosslinked scaffold materials were characterized using FTIR and 
compared with the available literatures. Adequate porosity of the scaffold material was confirmed 
by SEM and XMT techniques. However, more experiments are required to improve the bioactivity 
and mechanical strength of these scaffolds. The results obtained are useful and can funnel future 
research into experimentation with different bioactive glass fillers using larger crosslinking cations, 
such as strontium and barium, to improve the mechanical integrity of the alginates. Additionally, the 
bioactivity of the composite could be further enhanced by inclusion of nano-hydroxyapatite particles. 
Such material will provide a wide range of potential applications in the area of biomedical 
engineering. 
a b 
c d
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